C.M. Bidwell & Associates’s PDL BioPharma, Inc. PDLI Stock Holding History

C.M. Bidwell & Associates’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,120	Closed	-$3K	–	493
2018 Q2	$3K	Buy	+1,120	New	+$3.13K	﹤0.01%	371
2014 Q3	–	Sell	-17,335	Closed	-$168K	–	328
2014 Q2	$168K	Hold	17,335	–	–	0.04%	169
2014 Q1	$144K	Hold	17,335	–	–	0.03%	178
2013 Q4	$146K	Buy	+17,335	New	+$146K	0.04%	187

Other funds holding PDLI

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

C.M. Bidwell & Associates's PDLI Position: Q3 2018 in Review

C.M. Bidwell & Associates sold out of PDL BioPharma, Inc. (PDLI) in Q3 2018, closing a stake of 1,120 shares — an estimated $3K sold.

C.M. Bidwell & Associates first reported a position in PDLI in Q4 2013 and held it in 4 quarters. The position peaked at $168K in Q2 2014. 152 funds tracked by Wall St. Rank hold PDLI as of Q3 2018.

C.M. Bidwell & Associates reported no remaining PDL BioPharma, Inc. position as of Q3 2018 after selling out during the quarter.
C.M. Bidwell & Associates sold 1,120 PDL BioPharma, Inc. shares in Q3 2018, an estimated $3K.
C.M. Bidwell & Associates first reported a position in PDL BioPharma, Inc. in Q4 2013 and held it in 4 quarters.
C.M. Bidwell & Associates's PDL BioPharma, Inc. position peaked at $168K in Q2 2014.
152 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2018.

Based on C.M. Bidwell & Associates's 13F filing for Q3 2018, filed 13 Nov 2018.